VC fund profile · evidence-aware directory data
Two Sigma Ventures stages, portfolio and investment profile
Two Sigma Ventures was an early-stage technology investor that spun out as Deviation Capital in May 2026. Deviation now manages the legacy portfolio and pursues new investments in data-driven and technical companies. This page preserves the historical Two Sigma Ventures identity for older funding records.
Keep track of Two Sigma Ventures
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$1M–$10M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Seed, Series A
Participates: Pre-Seed, Seed, Series A, Series B+
Sector focus
ai-ml · deep-tech
Geography
Historical Two Sigma Ventures brand; successor Deviation Capital operates in New York and San Francisco
Founded 2012
Fund size / AUM
~$2B (Deviation, as of December 31, 2025; gross private-fund assets plus uncalled commitments, rounded to nearest $100M)
A separate fund-size evidence record is not yet available.
Portfolio in our directory
7
Linked startup profiles
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
Rounds they lead
Rounds they invest
Last verified: 2026-10-25. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Related reading
Recent investments, portfolio developments and our research on this investor.
Portfolio companies we track
Startups in our directory that list Two Sigma Ventures as an investor (7 total).
- Aradigm Benefits platform enabling sustainable employer access to cell and gene therapies.
- Arda Therapeutics Targeted cell-depletion therapies for chronic diseases using oncology modalities outside cancer.
- Distributional AI evaluation platform measuring production ML model quality, drift, and reliability.
- Insitro ML-driven drug discovery platform applying large-scale biology data to identify novel therapeutics.
- Osmo AI-powered digital olfaction — fragrance design via molecular data and machine learning.
- Recursion Techbio company using automated labs and ML for drug discovery at scale.
- Rive Real-time interactive animation platform and runtime for apps, games, and embedded UIs.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.